Ellipses Pharma
Charlotte Burmester is an experienced professional in clinical trial management and scientific research. Currently serving as an Associate Clinical Trial Manager at Ellipses Pharma since September 2022, Charlotte previously held positions as a Clinical Trial Associate and a Clinical Project Coordinator at Illingworth Research Group. In addition to the clinical research roles, Charlotte is the Podcast Host and Founder at Spectral Science, beginning in January 2025. Academic credentials include a Master of Science in Biological Sciences from the University of Birmingham, where research focused on the microbial impact on neural circuitry, culminating in a first honours degree with an 81% thesis score. Other experiences include working as a Covid Lab Tester at Lighthouse Labs and as an Analytical Science Placement Student at Pharmaron.
This person is not in any teams
This person is not in any offices
Ellipses Pharma
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments. Clinical trials are the route to developing more cancer treatments. All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients. We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective - making more treatments available to patients. Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel. Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.